Toward defining the threshold between low and high glucose variability in diabetes

Diabetes Care

Volumn 40, Issue 7, 2017, Pages 832-838

  Monnier, Louis ^a   Colette, Claude ^a   Wojtusciszyn, Anne ^b   Dejager, Sylvie ^c   Renard, Eric ^b   Molinari, Nicolas ^b   Owens, David R ^d  

^a UNIV MONTPELLIER   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; INSULINOTROPIC AGENT; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; COEFFICIENT OF VARIATION; CONTROLLED STUDY; DIET THERAPY; DYSGLYCEMIA; FEMALE; FRANCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; STATISTICAL ANALYSIS; UNIVERSITY HOSPITAL; BLOOD; MIDDLE AGED; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 85016207511     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1769     Document Type: Article

References (40)

1. TheDiabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetesmellitus. N Engl JMed 1993;329:977-986
2. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetic treatment and cardiovascular outcomes in type 1 diabetes: The DCCT/EDIC study 30-year follow-up. Diabetes Care 2016;39:686-693
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
4. Hayward RA, Reaven PD, Wiitala WL, et al.; VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;372:2197-2206
5. Monnier L, Colette C, Owens D. The glycemic triumvirate and diabetic complications: is the whole greater than the sum of its component parts? Diabetes Res Clin Pract 2012;95:303-311
6. Inzucchi SE, Bergenstal RM, Buse JB, et al.Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study ofDiabetes. Diabetes Care 2015;38:140-149
7. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687
8. Hirsch IB. Glycemic variability and diabetes complications: Does it matter? Of course it does! Diabetes Care 2015;38:1610-1614
9. Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care 2015;38:1615-1621
10. Probstfield JL, Hirsch I, O'Brien K, et al.; FLATSUGAR Trial Investigators. Design of FLAT-SUGAR randomized trial of prandial insulin versus prandial GLP-1 receptor agonist together with basal insulin and metformin for high-risk type 2 diabetes. Diabetes Care 2015;38:1558-1566
11. American Diabetes Association. Glycemic targets. Sec. 5. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl. 1): S39-S46
12. Monnier L, Colette C, Dejager S, Owens DR. NearnormalHbA1c with stable glucosehomeostasis: the ultimate target/aim of diabetes therapy. Rev Endocr Metab Disord 2016;17:91-101
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
14. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
15. World Medical Association Declaration of Helsinki.World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-926
16. Directive 2001/20/EC of the European Parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical trials on medicinal products for human use [Internet], 2001. Luxembourg, Official Journal of the European Communities. Available from https://www.eortc.be/services/doc/clinical-eu-directive-04-april-01.pdf. Accessed 15 December 2016
17. John WG, Braconnier F, Miedema K, Aulesa C, Piras G. Evaluation of the Menarini-Arkray HA 8140 hemoglobin A1c analyzer. Clin Chem 1997; 43:968-975
18. DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes 2013;62:1405-1408
19. Rodbard D. Clinical interpretation of indices of quality of glycemic control and glycemic variability. Postgrad Med 2011;123:107-118
20. Rodbard D. Hypo-and hyperglycemia in relation to the mean, standard deviation, coefficient of variation, and nature of the glucose distribution. Diabetes Technol Ther 2012;14: 868-876
21. Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009;11:551-565
22. Fabris C, Facchinetti A, Sparacino G, et al. Glucose variability indices in type 1 diabetes: parsimonious set of indices revealed by sparse principal component analysis. Diabetes Technol Ther 2014;16:644-652
23. Kohnert K-D, Heinke P, Fritzsche G, Vogt L, Augstein P, Salzsieder E. Evaluation of the mean absolute glucose change as ameasure of glycemic variability using continuous glucose monitoring data. Diabetes Technol Ther 2013;15:448-454
24. Weber C, Schnell O. The assessment of glycemic variability and its impact on diabetesrelated complications: an overview. Diabetes Technol Ther 2009;11:623-633
25. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, ClarkeW. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 1998;21:1870-1875
26. Kovatchev B, Cobelli C. Glucose variability: Timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care 2016;39: 502-510
27. Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev BP. Prediction of severe hypoglycemia. Diabetes Care 2007;30:1370-1373
28. Zar JH. Biostatistical Analysis. 4th ed. Upper Saddle River, NJ, Prentice Hall, 1999
29. FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care 2016;39:973-981
30. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl JMed 2005; 352:1685-1695
31. Monnier L, Wojtusciszyn A, Colette C, Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther 2011;13:813-818
32. Hirsch IB. Glycemic variability: it's not just about A1C anymore! Diabetes Technol Ther 2005;7:780-783
33. Midyett K, Cheung D, Unger JR, et al. Assessment of glucose variability by professional flash glucose monitoring across therapy groups for type 2 diabetes. Diabetes 2016;65(Suppl. 1):A222
34. Salkind SJ, Huizenga R, Fonda SJ, Walker MS, Vigersky RA. Glycemic variability in nondiabetic morbidly obese persons: results of an observational study and review of the literature. J Diabetes Sci Technol 2014;8:1042-1047
35. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007; 50:2553-2561
36. Cryer PE. Glycemic goals in diabetes: tradeoff between glycemic control and iatrogenic hypoglycemia. Diabetes 2014;63:2188-2195
37. Luijf YM, Avogaro A, Benesch C, et al.; AP@home consortium. Continuous glucose monitoring accuracy results vary between assessment at home and assessment at the clinical research center. J Diabetes Sci Technol 2012;6:1103-1106
38. American Diabetes Association Workshop on Hypoglycemia. Defining and reporting hypoglycemia in diabetes. Diabetes Care 2005;28: 1245-1249
39. Monsod TP, Flanagan DE, Rife F, et al. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care 2002;25:889-893
40. Guerci B, Floriot M, Böhme P, et al. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care 2003;26:582-589